ReproCell Delnica

ReproCell EBITDA

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) od ReproCell (4978.T) na dan 15. avg. 2026 je −111,96 Mio. JPY. V prejšnjem letu je EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) znašal −393,04 Mio. JPY — sprememba za −71,52 % (višje).

EBITDA

−111,96 Mio.JPY

YoY

−71,52%

Zadnja posodobitev:

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) od ReproCell je 2026 −111,96 Mio. JPY. EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) od ReproCell je bil 2025 −393,04 Mio. JPY. Pada za −71,52% višje v primerjavi s prejšnjim letom.
Access this data via the Eulerpool API

ReproCell Analiza delnic

Kaj dela ReproCell? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell je eno najbolj priljubljenih podjetij na Eulopoolu.

Pogosto zastavljena vprašanja o delnici ReproCell

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) podjetja ReproCell znaša −111,96 Mio. JPY v letu 2026.

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) od ReproCell se je spremenil z −393,04 Mio. JPY na −111,96 Mio. JPY, kar predstavlja spremembo za −71,52 %. Vrednost je višje kot v prejšnjem letu.

Na Eulopoolu najdete celovit zgodovinski razvoj EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo) ReproCell od leta 2006 – z letnimi vrednostmi, grafi in podrobno analizo.

EBITDA meri operativno učinkovitost pred vplivom finančne strukture, davčnega okolja in ne-gotovinskih stroškov amortizacije.

EBITDA = EBIT + Amortizacija in deprecijacija

EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo)s JPY je ključni dejavnik za vlagatelje. Spremembe te metrike lahko signalizirajo izboljšanje ali poslabšanje temeljnih podatkov, kar neposredno vpliva na ceno delnice. Na Euloolu lahko spremljate EBITDA (Dohodek pred obrestmi, davki, amortizacijo in depreciacijo)s ReproCell v realnem času in zgodovinsko.

Access this data via the Eulerpool API

Izkaz poslovnega izida — ReproCell

Vse ključne metrike — ReproCell